PepperLedger
COMPOUND LIBRARY·CAGRISEMA
COMPOUND PROFILE · PEPPERLEDGER

CagriSema

22.7% mean weight loss (REDEFINE 1, 68 weeks) · 40.9% achieved ≥25% weight loss · ~3× the weight loss of semaglutide alone
Type
Fixed-dose combination: Cagrilintide (long-acting amylin analog) + Semaglutide (GLP-1 receptor agonist)
Class
GLP-1/amylin combination — complementary mechanisms for weight loss and glycemic control
Developer
Novo Nordisk
Administration
Once-weekly subcutaneous injection
Half-life
Semaglutide component: ~7 days · Cagrilintide component: ~7 days
Most studied use
Obesity · Type 2 diabetes · Metabolic syndrome
Regulatory status
Not approved anywhere as of mid-2026 · Phase III REDEFINE program ongoing · REDEFINE 1 results published 2024/2025 · Earliest FDA approval 2026–2027
Human evidence
Strong — Phase III data published; 22.7% mean weight loss at 68 weeks in REDEFINE 1
Preclinical evidence
Strong — amylin + GLP-1 mechanism well-characterized

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is CagriSema?

CagriSema is Novo Nordisk's answer to the next generation of GLP-1 class therapeutics — a fixed-dose combination of semaglutide (their proven GLP-1 receptor agonist) with cagrilintide, a long-acting amylin analog. Where retatrutide (Eli Lilly's triple agonist) adds GIP and glucagon receptor agonism to GLP-1, CagriSema takes a different route: pairing GLP-1 with amylin, a pancreatic hormone that works synergistically through complementary and non-overlapping mechanisms.

Amylin is co-secreted with insulin by pancreatic beta cells and acts through its own receptors in the hypothalamus and brainstem. Its effects complement GLP-1: GLP-1 primarily suppresses appetite via hypothalamic pathways; amylin slows gastric emptying more potently and for longer than GLP-1 alone, reduces postprandial glucagon, and promotes satiety via area postrema signaling. The combination produces additive or synergistic effects through independent receptor systems.

Phase III REDEFINE 1 (2024/2025): 3,417 participants. CagriSema produced 22.7% mean weight loss at 68 weeks vs. 8.0% for semaglutide alone and 1.8% for placebo. 40.9% achieved ≥25% weight loss. These results position CagriSema as competitive with retatrutide and far superior to semaglutide alone — arriving from a different mechanistic direction.

How it works

GLP-1 Receptor Agonism (Semaglutide Component)

The semaglutide component provides the well-characterized GLP-1 mechanism: central appetite suppression via hypothalamic GLP-1R, slowed gastric emptying, glucose-dependent insulin secretion, and reduced glucagon. This is the proven foundation that the combination builds upon.

Amylin Receptor Agonism (Cagrilintide Component)

Amylin acts through amylin receptors (calcitonin receptor + receptor activity-modifying proteins) primarily in the area postrema and nucleus of the solitary tract — distinct from GLP-1R's primary sites. Amylin receptor activation: slows gastric emptying (more potently and durably than GLP-1 alone), reduces postprandial glucagon, and promotes gut-brain satiety signaling. Cagrilintide is a modified amylin analog with a half-life supporting once-weekly dosing.

How CagriSema Differs from Retatrutide

Retatrutide adds GIP and glucagon receptor agonism to GLP-1 — the glucagon arm specifically increases energy expenditure and drives direct lipolysis. CagriSema adds amylin receptor agonism to GLP-1 — the amylin arm specifically enhances caloric intake reduction through gastric emptying and brainstem satiety. Both produce similar weight loss outcomes, but through different mechanisms. No head-to-head data between the two exists yet.

What the research shows

PHASE III — HUMAN EVIDENCE
STUDYNew England Journal of Medicine · 2025

CagriSema vs. Semaglutide for Weight Loss (REDEFINE 1)

Novo Nordisk et al.

3,417 adults with obesity, 68 weeks. CagriSema: 22.7% mean weight loss. Semaglutide alone: 8.0%. Placebo: 1.8%. 40.9% of CagriSema participants achieved ≥25% weight loss. Significant GI side effects (nausea, vomiting) were the primary adverse event — more pronounced than semaglutide alone.

View on PubMed →
STUDYThe Lancet · 2021

Cagrilintide Phase II — Dose Finding and Safety

Enebo LB, Berthelsen KK, Kankam M et al.

706 adults with obesity. Cagrilintide monotherapy 2.4 mg: 15.6% weight loss at 26 weeks. Established cagrilintide's standalone weight-loss profile before the combination trial. Severe nausea in first weeks was the primary limiting factor.

View on PubMed →
WHAT THE RESEARCH SHOWS
✓KNOWN
  • ✓22.7% mean weight loss at 68 weeks (REDEFINE 1 Phase III)
  • ✓Superior to semaglutide alone (~22.7% vs ~8%) — ~3× the weight loss
  • ✓GI side effects more pronounced than semaglutide alone during escalation
  • ✓Amylin + GLP-1 mechanism well-characterized
  • ✓40.9% of participants achieved ≥25% weight loss
?UNCERTAIN
  • ?Long-term outcomes beyond 68 weeks
  • ?Cardiovascular outcomes trial not yet reported
  • ?Post-discontinuation weight rebound (expected to mirror semaglutide pattern)
  • ?Head-to-head vs. retatrutide or tirzepatide
  • ?Lean mass effects at this magnitude of weight loss

What the community reports

CagriSema's community is primarily people following the next-generation metabolic therapeutics space closely — those who have used semaglutide or tirzepatide and are tracking what comes next. Because it's investigational and not widely available off-label yet, community use is less extensive than for retatrutide. The comparison to retatrutide is the dominant community conversation — both produce ~22–29% weight loss through different mechanisms. Some users are running self-constructed combinations of compounded cagrilintide with their existing semaglutide protocols.

Common misconceptions

"CagriSema and retatrutide are the same thing."

REALITY

Both are next-generation metabolic compounds beyond semaglutide, but mechanistically different. CagriSema = GLP-1 + amylin. Retatrutide = GLP-1 + GIP + glucagon. The weight loss outcomes are similar; the mechanistic paths are different. Retatrutide's glucagon arm drives energy expenditure; CagriSema's amylin arm drives gastric emptying control and brainstem satiety.

"CagriSema is just semaglutide with an add-on."

REALITY

The 22.7% vs. 8.0% weight loss in REDEFINE 1 shows CagriSema meaningfully outperforms semaglutide alone — nearly three times the weight loss. The amylin component is not a minor addition; it's a significant mechanistic contribution through independent receptor systems.

"Phase III success means FDA approval is imminent."

REALITY

Phase III success is necessary but not sufficient for approval. Novo Nordisk still needs to file a BLA and FDA needs to review it. Earliest plausible approval is 2026–2027 — soon, but not immediate.

COMPARE — NEXT GENERATION METABOLIC

Retatrutide — GLP-1/GIP/glucagon triple agonist, 28.7% weight loss (Phase 3). Different mechanism, similar headline outcomes. Tirzepatide and Semaglutide — currently approved options.

AI COACH PREVIEW
How does CagriSema compare to retatrutide? I'm trying to decide what to pursue when approved.
This is the question the entire next-generation metabolic therapeutics community is working through right now, because there's no head-to-head data. Here's how to think about it. Headline weight loss numbers: CagriSema 22.7% (REDEFINE 1, 68 weeks) vs. retatrutide 24.2% (TRIUMPH-4, 48 weeks) — essentially equivalent within the margin of different trial designs. Neither has shown a clear superiority over the other for the primary weight loss endpoint. Mechanism differences that may matter for you specifically: CagriSema's amylin arm is primarily an enhanced caloric intake reduction tool — more potent gastric emptying control and brainstem satiety signaling than semaglutide alone. If your primary challenge is portion control and postprandial satiety, CagriSema addresses that more aggressively. Retatrutide's glucagon arm increases energy expenditure and drives direct lipolysis — if your primary challenge is metabolic rate or visceral fat specifically, retatrutide's glucagon mechanism addresses that more directly. GI side effects: both have more pronounced GI effects than semaglutide alone. CagriSema's amylin-compounded gastric emptying slowing may produce more nausea in some people; retatrutide's profile is from its own trial population. Neither is clearly easier to tolerate — individual responses vary. Practical consideration: whichever is approved first in your market and available through your prescriber wins. Both require prescription. The mechanistic argument for picking one over the other is secondary to access. Cardiovascular outcomes: semaglutide has SELECT (26% CV event reduction). Neither CagriSema nor retatrutide has a published CV outcomes trial yet. If cardiovascular risk reduction is a primary goal, semaglutide currently has the evidence advantage over both. What's your primary goal — maximum weight loss, metabolic health, or cardiovascular risk reduction? That frames which of these is most relevant for your situation.
CONTINUE IN THE APP

Open PepperLedger to track your GLP-1 combination protocol →

Free to join. No credit card. Track your metabolic protocol and ask the Coach.

Free to join · No credit card · 23-day Pro trial included

PepperLedger

Educational tool — not medical advice. PepperLedger is a logging and information tool for adults managing their own protocols. It does not prescribe, diagnose, or treat anything. Always work with a qualified healthcare provider for medical decisions.

CagriSema is not FDA-approved. Educational tool — not medical advice. Consult a healthcare provider for GLP-1 class treatment options currently available.

© 2026 Realee AI · PepperLedger